The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO GI 2021 | NEPAFOX: adjuvant gemcitabine vs. FOLFIRINOX in resectable pancreatic cancer

Name: NEPAFOX: adjuvant gemcitabine vs. FOLFIRINOX in resectable pancreatic cancer
Uploaded: 2021-01-22T00:00:00Z
Duration: 1 min 38 s
Description: Thorsten Goetze, MD, University Cancer Center Frankfurt, Frankfurt, Germany, discusses results from the NEPAFOX trial (NCT02172976), a randomized multicenter Phase II/III study investigating adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Thorsten Götze • 22 Jan 2021

ASCO GI 2021

Gastrointestinal Cancer Pancreatic Cancer Folfirinox Gemcitabine

NEPAFOX

Thorsten Goetze, MD, University Cancer Center Frankfurt, Frankfurt, Germany, discusses results from the NEPAFOX trial (NCT02172976), a randomized multicenter Phase II/III study investigating adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).